PT Diagnos Laboratorium Utama Tbk

IDX:DGNS Stock Report

Market Cap: Rp247.5b

Diagnos Laboratorium Utama Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mesha Sini

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure4.2yrs
CEO ownershipn/a
Management average tenure2.7yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO

Mesha Sini (51 yo)

4.2yrs

Tenure

Ir. Mesha Rizal Sini, M. Eng, SH, is President Director of PT Diagnos Laboratorium Utama Tbk since October 13, 2020. He is a Commissioner of PT Bunda Investama Indonesia since 2019. He is Commissioner of P...

Leadership Team

NamePositionTenureCompensationOwnership
Mesha Sini
President Director4.2yrsno datano data
Dilly Dwiasri
Director of Operations & Marketing and Director2.4yrsno datano data
Martinus Zega
GM of Sales & Independent Commissionerno datano datano data
Fergus Richard
MD & Directorless than a yearno datano data
Maurina Dwiyanthi
Head of Internal Audit Unit & Manager of SPI2.7yrsno datano data
Fanfan Riksani
Corporate Secretary4.2yrsno datano data

2.7yrs

Average Tenure

46yo

Average Age

Experienced Management: DGNS's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mesha Sini
President Director4.2yrsno datano data
Dilly Dwiasri
Director of Operations & Marketing and Director2.4yrsno datano data
Martinus Zega
GM of Sales & Independent Commissioner1.9yrsno datano data
Fergus Richard
MD & Director2.4yrsno datano data
Nurhadi Yudiyantho
Commissioner4.2yrsno datano data
Ivan Sini
President Commissioner4.2yrsno datano data
Renobulan Rizal Suheimi
Director4.2yrsno datano data
Agus Darjono
Directorless than a yearno datano data

3.3yrs

Average Tenure

51yo

Average Age

Experienced Board: DGNS's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 14:39
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Diagnos Laboratorium Utama Tbk is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution